Prais, Dario
3 papers on CoChatORCID 0000-0002-4165-0144
Most cited papers
- Verified
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Davies, J. C., Moskowitz, S. M., Brown, C., Horsley, A., Mall, M. A., McKone, E. F., Plant, B. J., Prais, D., Ramsey, B. W., Taylor-Cousar, J. L., et al. (2018) · New England Journal of Medicine
Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery
Cited by 331
- Verified
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
Flume, P. A., Biner, R. F., Downey, D. G., Brown, C., Jain, M., Fischer, R., De Boeck, K., Sawicki, G. S., Chang, P., Paz-Diaz, H., et al. (2021) · The Lancet Respiratory Medicine
Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery
Cited by 52
- Verified
Presence of D8/17 B-cell marker in patients with poststreptococcal reactive arthritis
Harel, L., Mukamel, M., Zeharia, A., Kodman, Y., Prais, D., Uziel, Y., Zabriskie, J. B., & Amir, J. (2007) · Rheumatology International
Streptococcal Infections and TreatmentsSpondyloarthritis Studies and Treatments
Cited by 11
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free